PrabotulinumtoxinA Disease Interactions

The administration of prabotulinumtoxinA is contraindicated in the presence of infection at the proposed injection site(s).

The administration of prabotulinumtoxinA may cause cardiovascular adverse events, including arrhythmia and myocardial infarction, some with fatal outcomes. It is recommended to monitor and use caution when using this agent in patients with preexisting cardiovascular disease.

The administration of botulinum toxin products, including prabotulinumtoxinA can result in swallowing or breathing difficulties. Patients with preexisting swallowing or breathing difficulties may be more susceptible to these complications. Patients treated with botulinum toxin products may require immediate medical attention should they develop problems with swallowing, speech or breathing. These reactions can occur within hours to weeks after injection with botulinum toxin. Caution is recommended when using this agent in patients at risk.

The administration of prabotulinumtoxinA to patients with preexisting neuromuscular disorders may increase the risk of clinically significant effects, including generalized muscle weakness, diplopia, ptosis, dysphonia, dysarthria, severe dysphagia and respiratory compromise. Exercise care when using this agent in patients at risk.